Lifespan Analysis of 212 Transplanted Kidney Grafts: Effects of Use of Humanized Anti–IL-2R Monoclonal Antibody in Graft Survival at 1, 3, and 5 Years for 108 Recipients

Abstract 

Introduction

The use of new drugs and new immunossupressant schemes, as well as induction therapy with anti-IL-2R monoclonal antibody has significantly contributed to prolonged renal graft survival, especially in cadaveric grafts. However, what has led to this improvement has not been defined yet.

Objective

Analyze the outcome of induction of humanized anti-IL-2R monoclonal antibodies on 1, 3 and 5 year survivals of 212 renal transplants from 1999 to 2005.

Method

We analyzed the lifespan of grafts using Kaplan-Meier curves, using a significance level of α = 0,05 for 212 renal allografts.

Results

The global result for 1, 3 and 5 year survival curves of patients who received the induction therapy was 88%, 86% and 86%, and for recipients who did not receive induction was 81%, 81% and 81%, respectively. Likewise, cadaveric donors who received induction displayed 88%, 88% and 88%, and those who did not receive it 62%, 62% and 62% (p = 0,0089).

Conclusion

Despite the time and the number of transplants using induction therapy being modest, at 1, 3 and 5 years there was an increased lifespan, especially for cadaveric grafts, among patients who received induction, with IL2Ra antibodies.